TrialJournal of psychopharmacology (Oxford, England)2021

Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.

Nicholas R Livingston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.